Objectives: Long non-coding RNA cancer susceptibility candidate 2 (CASC2) is a novel lncRNA and has been indicated as playing tumour suppressor gene in several tumours.
| INTRODUCTION
Osteosarcoma is one of the most common primary bone malignancies in adolescents and children that is mainly localized in the metaphysis of the long bones. [1] [2] [3] [4] [5] With the improvements of osteosarcoma therapeutic strategies including adjuvant chemotherapy, radiotherapy and wide tumour excision, the 5-year survival rate of osteosarcoma cases without metastatic disease is improved to 65%. [6] [7] [8] [9] However, a half of patients will develop metastases and few of these patients could be cured. [10] [11] [12] Therefore, it is urgent to find new biomarkers and therapeutic targets for osteosarcoma patients.
Long non-coding RNAs (lncRNAs) are one major members of ncRNA family that are >200 bases in length with limited protein coding capacity. [13] [14] [15] [16] Recent researches have demonstrated that the expression of lncRNAs was deregulated in many types of tumours.
17-20
Increasing evidences have showed that lncRNAs play essential roles in a variety of cell biological processes such as cell development, proliferation, apoptosis, invasion, metastasis and stem cell pluripotency.
18,
21-23 lncRNA cancer susceptibility candidate 2 (CASC2) is a novel lncRNA that is located in human 10q26 and acts as a tumour suppressor gene in several tumours such as endometrial cancer, bladder cancer and gastric cancer. [24] [25] [26] [27] However, the expression and functional role of CASC2 in the development of osteosarcoma are still uncovered.
In this study, we try to analyse the expression of CASC2 in the osteosarcoma cell lines and tissues. We also investigated the role of CASC2 in osteosarcoma cell.
| MATERIALS AND METHODS

| Human tissue samples
The 40 osteosarcoma tissues and the matched non-cancerous samples utilized in our study were obtained from The Fifth Hospital of
Harbin. This study was approved by The Fifth Hospital of Harbin Institutional Review Board. All patients were provided the informed consent for using of their tissues in our research.
| Cell culture and transfect
The human osteosarcoma cell lines MG-63, SW1353, Saos-2, SOSP-9607 and U2OS and human osteoblasts hFOB were obtained from the 
| Quantitative real-time RT-PCR (qRT-PCR) analysis
Total RNA was isolated from cells or tissues using the TRIzol kit 
| Cell proliferation, invasion and colony formation assay
The cell proliferation was analysed by CCK-8 assay (DOJINDO, Tokyo, Japan) in accordance with the manufacturer's instructions. 
| Western blot analysis
Protein from cells or tissues was extracted by a lysis buffer, and the concentration of protein was determined using the Bicinchoninic Acid (BCA)
protein assay (Santa Cruz, CA, USA) according to the manufacturer's instructions. Equal protein was separated by 10% SDS-PAGE and transferred onto the nitrocellulose membranes (Millipore Corporation, Boston, MA, USA). Membrane was blocked 5% non-fat milk and then incubated with primary antibodies (RASSF6 and GAPDH, Abcam, Cambridge, UK) at 1:5000 dilutions. The membrane was incubated with secondary antibody for 1 hour at the room temperature. Protein band was determined by the enhanced chemiluminescence (ECL) detection system.
| Statistical analysis
The data were shown as the mean ± standard deviation (SD) and measured using SPSS18.0 statistical software (IBM, Chicago, IL, USA). Differences were determined by the two-tailed Student's t test. The relationship between CASC2 and RASSF6 expressions was assessed with two-tailed
Pearson's correlation. P < .05 was defined as statistically significant.
| RESULTS
| CASC2 expression was downregulated in osteosarcoma tissues
We firstly explored CASC2 expression in osteosarcoma samples (n = 35) compared with non-tumour tissues (n = 35) using qRT-PCR.
As shown in the Figure 1A ,B, CASC2 expression was significantly decreased in osteosarcoma samples compared with non-tumorous samples. Moreover, we showed that downregulated expression of CASC2 was correlated with advanced TNM stage ( Figure 1C ).
| CASC2 suppressed osteosarcoma cell proliferation
We determined the expression of CASC2 in osteosarcoma cell lines. As shown in the Figure 2A , the CASC2 expression was downregulated in osteosarcoma cell lines (MG-63, U2OS, SOSP-9607 and Saos-2) compared with human osteoblasts cell line (hFOB). To further study the role of CASC2 in osteosarcoma cell, the pcDNA-CASC2 was designed and transfected into MG-63 and U2OS cells. As shown in Figure 2B ,C, cells transfected with pcDNA-CASC2 had a remarkably increased CASC2 expression compared with the control vector group in both cell lines by qRT-PCR. In addition, overexpression of CASC2 suppressed MG-63 ( Figure 2D ) and U2OS ( Figure 2E ) cell proliferation.
| CASC2 inhibited osteosarcoma cell colony formation and invasion
To further examine the influence of CASC2 on osteosarcoma cell invasion, we performed transwell assays in MG-63 and U2OS cells.
Elevated expression of CASC2 suppressed MG-63 and U2OS cell invasion ( Figure 3A ). In addition, we performed a colony formation assay to further study the role of CASC2 on osteosarcoma cell growth.
Consistently, we found that ectopic expression of CASC2 decreased the MG-63 and U2OS cell colony formation ( Figure 3B ).
F I G U R E 1 Cancer susceptibility candidate 2 (CASC2) expression was downregulated in the osteosarcoma tissues. A, The expression of CASC2 in the osteosarcoma samples and non-tumour tissues was determined by qRT-PCR. U6 was used as the internal control. B, The CASC2 expression level in the osteosarcoma samples was lower than in the non-tumorous samples. C, The lower expression of CASC2 was associated with the advanced TNM stage. *P < .05 F I G U R E 2 Cancer susceptibility candidate 2 (CASC2) suppressed the osteosarcoma cell proliferation. A, The expression of CASC2 in the osteosarcoma cell lines (MG-63, U2OS, SOSP-9607 and Saos-2) and human osteoblasts cell line (hFOB) was measured by qRT-PCR. U6 was used as the internal control. B, The expression level of CASC2 in the MG-63 cell with transfecting pcDNA-CASC2 vector was determined using qRT-PCR. C, The expression level of CASC2 in the U2OS cell was measured by qRT-PCR. D, Ectopic expression of CASC2 decreased the MG-63 proliferation. The cell proliferation was determined by CCK-8 assay. E, CCK-8 assay was performed to measure the U2OS cell proliferation. *P < .05, **P < .01 and ***P < .001
F I G U R E 3 Cancer susceptibility candidate 2 (CASC2) inhibited the osteosarcoma cell colony formation and invasion. A, Elevated expression of CASC2 decreased the MG-63 and U2OS cell invasion. Relative ratio of invasive cells per field is shown. B, Ectopic expression of CASC2 suppressed the MG-63 and U2OS cell colony formation. The relative colony numbers were shown. ***P < .001
| CASC2 suppressed miR-181a expression in osteosarcoma cell
Next, we demonstrated that ectopic expression of CASC2 decreased miR-181a expression in the MG-63 cell ( Figure 4A ).
In addition, we showed that overexpression of CASC2 enhanced RASSF6 expression in the MG-63 cell ( Figure 4B ). Moreover, we demonstrated that elevated expression of CASC2 promoted the expression of PTEN ( Figure 4C ) and ATM ( Figure 4D ) in the MG-63 cell.
| RASSF6 expression was downregulated in osteosarcoma tissues
We then explored the RASSF6 expression in osteosarcoma samples (n = 35) compared with non-tumour tissues (n = 35) using qRT-PCR.
The RASSF6 expression was significantly decreased in osteosarcoma samples compared with non-tumorous samples ( Figure 5A,B) .
Moreover, we showed that downregulated expression of RASSF6 was correlated with advanced TNM stage ( Figure 5C ). In addition,
we found that the expression of RASSF6 was positively correlated with the expression of CASC2 in osteosarcoma tissues ( Figure 5D ).
As shown in Figure 5E , the RASSF6 expression was downregulated in osteosarcoma cell lines (MG-63, U2OS, SOSP-9607 and Saos-2) compared with human osteoblasts cell line (hFOB).
| CASC2 suppressed osteosarcoma cell proliferation, colony formation and invasion through regulating RASSF6 expression
To further study the role of RASSF6 in osteosarcoma cell, si-RASSF6 was designed and transfected into MG-63 cells. As shown in Figure 6A , cells transfected with si-RASSF6 had a remarkably decreased RASSF6 expression compared with the control vector group in the MG-63 cell.
The protein expression of RASSF6 was also decreased in the si-RASSF6 group ( Figure 6B ). Next, si-RASSF6 or control vector was transfected into the CASC2-overexpressing MG-63 cell. We found that knockdown of RASSF6 promoted the CASC2-overexpressing MG-63 cell proliferation, colony formation and invasion ( Figure 6C ,D,E).
| DISCUSSION
Increasing evidence has showed that lncRNAs act vital roles in more biological processes. 28, 29 Many studies demonstrated that lncRNAs Relative ratio of invasive cells per field is shown. *P < .05, **P < .01 and ***P < .001
were deregulated in several tumours and lncRNAs played as cancer suppressors or oncogenes, contributing to tumour pathogenesis and progression. [30] [31] [32] [33] In our study, we showed that CASC2 expression Overexpression of CASC2 inhibited colorectal cancer cell proliferation and tumour growth through regulating the miR-18a/PIAS3 expression.
However, the expression and role of CASC2 in osteosarcoma are still unclear. In this study, we manifested that CASC2 expression was downregulated in osteosarcoma tissues and cell lines. Overexpression of CASC2 inhibited osteosarcoma cell proliferation, colony formation and invasion.
However, the mechanism about how CASC2 affects the function of osteosarcoma cell remains to be studied. It has been shown that lncRNAs play as a "Sponge" of miRNA to decrease their effect on mRNAs. is one member of C-terminal RASSF protein such as RASSF3 and RASSF1A. 45, 46 The expression of RASSF6 was downregulated in several tumours such as gastric cancer, hepatocellular carcinoma, colorectal cancer and pancreatic ductal adenocarcinoma. [47] [48] [49] RASSF6 played as a tumour suppressor gene and suppressed tumour cell growth, invasion and migration and promoted the cell cycle and apoptosis. 48, 50 In this study, we demonstrated that RASSF6 expression was downregulated in osteosarcoma tissues and cell lines and downregulated expression of RASSF6 was correlated with advanced TNM stage. Moreover, the expression of RASSF6 was positively correlated with the expression of CASC2 in osteosarcoma tissues. Furthermore, we showed that ectopic expression of CASC2 decreased osteosarcoma cell proliferation, colony formation and invasion through regulating RASSF6 expression.
In conclusion, our data revealed that CASC2 expression was downregulated in osteosarcoma tissues and cell lines and overexpression of CASC2 suppressed osteosarcoma cell growth, colony formation and invasion through regulating miR-181a/RASSF6 expression. This study suggested that CASC2 might serve as a tumour suppressor lncRNA in the development of osteosarcoma.
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